Compare AEVA & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEVA | SDGR |
|---|---|---|
| Founded | 2019 | 1990 |
| Country | United States | United States |
| Employees | 276 | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 819.5M | 856.7M |
| IPO Year | N/A | 2020 |
| Metric | AEVA | SDGR |
|---|---|---|
| Price | $15.47 | $12.61 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $26.50 | $21.75 |
| AVG Volume (30 Days) | ★ 1.5M | 1.2M |
| Earning Date | 01-01-0001 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.14 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $255,869,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $132.72 | $7.69 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 23.29 |
| 52 Week Low | $2.90 | $11.11 |
| 52 Week High | $38.79 | $27.63 |
| Indicator | AEVA | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 56.07 | 48.71 |
| Support Level | $12.28 | $11.11 |
| Resistance Level | $18.19 | $13.36 |
| Average True Range (ATR) | 1.33 | 0.73 |
| MACD | 0.22 | 0.20 |
| Stochastic Oscillator | 54.69 | 70.94 |
Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The company operates in North America, EMEA, and Asia. The company derives the majority of its revenue from North America.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.